PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary OpGen Provides Business and Preliminary Financial Update
GAITHERSBURG, Md. , Oct. 15, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today provided an update on its commercial activities and clinical trials for its Acuitas® AMR Gene Panel tests and the Acuitas Lighthouse® Software. Preliminary unaudited results for the third quarter of 2018 were
View HTML
Toggle Summary OpGen to Present at Two Upcoming Investment Conferences in October
GAITHERSBURG, Md. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) announced today that Evan Jones , Chairman and Chief Executive Officer, will present a corporate overview at two upcoming investment conferences, as follows: Ladenburg Thalmann 2018 Healthcare Conference   Date and
View HTML
Toggle Summary OpGen Partnering with New York State Department of Health and Merck’s ILÚM Health Solutions to Detect Antimicrobial-Resistant Infections
Collaboration with NY Department of Health’s Wadsworth Center to utilize OpGen’s Acuitas AMR Gene Panel u5.47 and Acuitas Lighthouse Software within Statewide digital health and precision medicine platform at healthcare institutions statewide GAITHERSBURG, Md. , Sept.
View HTML
Toggle Summary OpGen to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
GAITHERSBURG, Md. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) announced today that Evan Jones , Chairman and Chief Executive Officer, will present a corporate overview at the 20 th Annual Rodman & Renshaw Global Investment Conference , sponsored by H.C.
View HTML
Toggle Summary OpGen Reports Second Quarter 2018 Financial Results And Provides Business Update
Revenue increases 12% to $0.8 million , net loss narrows 21% to $3.3 million Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today reported financial and operating results for the three and six months ended June
View HTML
Toggle Summary OpGen Announces Date of Second Quarter 2018 Financial Results Conference Call
GAITHERSBERG, Md., July 25, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that the Company will report financial results for the three and six months ended June 30, 2018 after close of the U.S. financial markets on Thursday, August 2, 2018 .
View HTML
Toggle Summary OpGen Modifies Terms of Debt with Merck Global Health Innovation Fund
GAITHERSBERG, Md., June 14, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it has negotiated modifications related to its $1,000,000 Second Amended and Restated Senior Secured Promissory Note (the “Note”), dated June 28, 2017 , to extend the maturity of the note and to pay
View HTML
Toggle Summary OpGen Presents Data at ASM Microbe 2018 Demonstrating High Accuracy of Acuitas® for Predicting Antibiotic Resistance in Urine Specimens
90% accuracy data presented for rapid antibiotic resistance prediction using Acuitas AMR Gene Panel and Acuitas Lighthouse on urine clinical specimens Prospective clinical trial in Colombia demonstrates 57% improvement in survival and reductions in antibiotic usage when OpGen rapid diagnostic test
View HTML
Toggle Summary OpGen’s Acuitas® AMR Gene Panel u5.47 Data to be Presented at ASM Microbe 2018
Company Sponsors Symposium on Rapid Pathogen Detection and Prediction of Antimicrobial Resistance in Urinary Tract Infections GAITHERSBURG, Md. , June 05, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that data on its Acuitas ® AMR Gene Panel u5.47 (RUO) and Acuitas Lighthouse
View HTML
Toggle Summary OpGen Reports First Quarter 2018 Financial Results and Provides a Business Update
Revenue increases 10% to $0.8 million , net loss decreases 39% to $3.0 million Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md. , May 08, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today reported financial and operating results for the three months ended March 31,
View HTML